Category Archives: Genetic Engineering

While 70 million Americans are under lockdown to contain spread of the 2019 form of coronavirus, SARS-CoV-2, in order to limit the spread of the COVID-19 illness that has cost 16,000 lives worldwide, American lawyers are teeing up to sue the one product the FDA and everyone else knows kills germs - Purell.

While political activists are yelling that hotels forced by threat of law to remain closed should not get any sort of government bailout, where is the yelling that other lawyers are profiteering from fear and doubt?It isn't just in the U.S. In Italy, a lawyer is trying to drum up support in a communist newspaper thatmodern genetic engineering makes coronavirus easier to spread.

Meanwhile, the philosopher Vandana Shiva, Ph.D, an avowed opponent of farming, is using the outbreak to promote her agenda against science.

Communists and anti-science activists and trial lawyers working together? Who saw that coming?

Well, everyone. Dark money runs deep in the environmental movement. In 2015, James Clapper, Director of National Intelligence during the Obama administration, warned that Russia was using offshore "donor advised" funds to send money to its allies in the US. And those allies in the US are a Who's Who of environmental groups opposed to farming and energy, Russia's top-two exports. COVID-19 ended up being kind of a win for China, since they had just been exposed as paying numerous American academics to help recruit others in the communist country's effort to move ahead of America.

Now those same groups are claiming that people who don't eat organic food are more susceptible to coronavirus. It's working. Some organic farms are reporting that their online sales have tripled.

It's a disgusting, despicable tactic that unfortunately works, no less successful than Dr. Shiva claiming that modern farming causes suicides and those who don't agree with her are rapists. Facts don't matter, greed does, and she makes $40,000 per speech promoting hatred of science.

View post:
What Anti-Science Activists And Lawyers Have In Common During This Crisis They Share The Rest Of The Time: Fear Profiteering - Science 2.0

The impact of COVID 19 is far-reaching and profound. The virus is unseen and moving fast. It can infect without symptoms. Its use of innocent carriers makes everyone suspect.

It also attacks in a random fashion, with just enough victims to easily lead the rest to the edge of panic. And while COVID 19 appears to kill 20 to 30 times more people than the worst form of flu, it seems to still be like a common cold, in that it may not be strong enough for the body to develop a lasting immune system response.

In spite of the earlier hype, artificial intelligence (AI) has singularly failed to help much.

There was little in the way of predictive analytics about where the pandemic would strike and how it would develop.

The jury is also out on another much-touted darling, biotechnology. Biotech has yet to offer anything like a silver bullet.

Meanwhile, the entire world waits with baited breath for a designer drug or vaccine spliced and stitched up with genetic engineering tools like CRISPR, to vanquish COVID 19.

At the present stage, we cant even answer very simple questions: What comes when this current peak wanes?

All we seem to know is that there will be a new normal. For the foreseeable future, it may not be like anything before.

There is even a good chance some of the same questions we now face may still be around during the next peak of infections, and the one after.

Amidst all this hand-wringing and unleashing of previously unseen economic rescue packages, only the Anglo-Saxons and the Calvinist Dutch have asked the Mother of all Questions:

Who is prepared to pay the price for an abnormal, new normal ? And what exactly will this look like?

The first victim of COVID 19 is likely to be tourism. Which matters because it is one of the worlds biggest economic sectors.

The era of retirement voyages on cruise ships is probably sunk for good. But what about airlines, the lifeblood of the 21st centurys globalized economy?

After all, this is an industry where passengers are even far more densely packed than on cruise ships, sitting squeezed together for hours on end in an air-tight tube.

Worse, owing to the industrys mantra of operating a hub-and-spokes system at airports, a single asymptomatic carrier may be enough to kindle a burgeoning cycle of infections in many different countries.

That evidently is what happened at resorts in Austria and Italy during that fateful ski holiday week at the end of February.

Note as well that, in 2003 when COVID 19s SARS cousin sprouted in China, 1.65 billion people travelled by air that year. In 2018, the figure was already two-and-a-half times higher, at 4.2 billion.

Moving up and down the economic value chain produces only more of the same uncomfortable questions.

Here are some of the pertinent questions to be asked:

1. What is the business outlook for AirBnB, co-living, bars and cafes, discos and cinemas, open-air markets?

2. Will remote learning be the death knell for brick-and-mortar university campuses?

3. How virus-proofed are food and fruit supply chains from Spain to northern Europe, from Mexico to the United States?

4. Do the lorries backed up at borders within the Schengen area conceal refugees?

5. At a time when emergency services are stretched, what is the chance of a terror attack, and how effective would be a response?

6. And although it is clear that a lockdown reduces most targets for a mass casualty attack, there is one notable exception the public hospital.

Most of the world remains hopeful about vaccination against COVID 19. However, a successful vaccine is unlikely to be ready before the end of this year.

After this, there will be the challenge of ramping up production and organizing the immunization of billions of people.

In the meanwhile, should one or more pharmacological treatments be successful, the question remains: How many can be treated, and where?

With 5-10% of COVID 19 cases needing ventilator support, is there room for drive-in halfway houses, between home and hospital, or hospital and intensive care?

In many parts of Europe, serious debate about such questions have been derailed by newsbytes and occasional self-congratulation about hospitals and ICUs.

Way beyond this, tough questions need to be faced. One of the most immediate issues is strategic self-sufficiency.

Take the case of Germany, the presumed master of infrastructure spending and planning. With war out of fashion in Europe, little attention was given to the amazing finding that a large part of Germanys fighter jets, helicopters, tanks and submarines did not work when tested.

This was largely an ideological battle between the left and the political center. However, public health should be another matter.

Nobody is really surprised that there was a severe shortage of face masks even in hospitals in Italy. But why on earth is there one in Germany?

Health systems in ageing societies may lack nurses and lab technicians but face masks?

Just how off we are on our presumably modern reaction and thought patterns, consider this: Before the COVID 19 crisis, the world was obsessed about plastics, of doing away with them.

As is ironically turns out now, the best defense against viral contamination is a plastic barrier. All of a sudden everybody prays for plastics Great Return.

Amidst the many ethics questions we will have to ponder, there are two lessons which COVID 19 might teach us.

1. To pay for the panoply of ever-cheaper products we do not really need, we have lived our lives on a curve of diminishing returns. There will be a recession, probably a severe one, but the world economy will recover. To what degree is our choice.

2. As we sit locked down at home, we can celebrate the return of time. We do not need to overwork to save for free time, at a later date.

It may also be salutary to remember that refugees did not cause the 21st centurys first pandemic. Tourists did.

Link:
COVID 19: 21st Century Reality Check - The Globalist

PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer. These naturally occurring or modified viruses are a potent new weapon against cancer, according to recent reports on this growing market. The reports actually reveal that: " since the late 1800s, doctors have observed that some patients with cancer go into remission, if only temporarily, after a viral infection. Although the notion of using viruses in cancer therapy is old, the science only began to move forward in the 1990s with advances in genetic engineering technology with another shift around 2005, as people began to realize the true value of viruses in cancer therapy is in immunotherapy. When an oncolytic virus infects a tumor cell, it makes copies of itself until the cell bursts. The dying cancer cell releases tumor antigens and/or danger signals, which can change the tumor microenvironment to change an immunologically "cold" tumor (lacking T cells) into a "hot" tumor (influx of a multitude of immune cells and cytokines). Oncolytic viruses are alerting the immune system that something is wrong. This can lead to an immune response against nearby tumor cells (a local response) or tumor cells in other parts of the body (a systemic response)." Active biotech and pharma companies in the markets this week include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Hoth Therapeutics, Inc. (NASDAQ: HOTH), ADMA Biologics, Inc. (NASDAQ: ADMA), Pfizer Inc. (NYSE: PFE), Aytu BioScience, Inc. (NASDAQ: AYTU).

Oncolytic viruses are naturally occurring or genetically modified to target specific types of cancer cells. They selectively replicate within the cancer cell via a tumor-specific promoter element that is incorporated into the viral genome or in deletions in key portions of the viral genome. The oncolytic viruses must be genetically stable and be incapable of reverting back to its wild-type form while replicating inside cancer cells. In addition, transgenes encoding interferon alpha, granulocyte macrophage colony stimulating factor (GM-CSF), and multiple cytokines have been inserted into oncolytic viruses to achieve a variety of immunomodulatory effect. The size of the oncolytic viral genome affects the transgene capacity, which makes certain oncolytic virus with larger genome more desirable.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) BREAKING NEWS: Oncolytics Biotech Announces Favourable AWARE-1 Safety Update- Oncolytics Biotech currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1.Consistent with the safety run-in with patients receiving pelareorep and Tecentriq, Cohort 1 demonstrated widespread viral replication in the majority of tumors with the creation of a pro-inflammatory effect in the tumor microenvironment. No negative effects to healthy tissue were noted.

The Committee evaluated safety parameters from patients participating in the safety run-in phase of the trial, consisting of select patients from cohorts 2 and 3, along with the fully enrolled cohort 1, and determined there were no safety concerns.The Committee also approved an amendment of the study to reduce the dose of Tecentriq to be consistent with the currently approved breast cancer dose of 840mg.The study will continue to enroll patients and the Safety Committee will meet again for an additional pre-planned meeting. Cohorts 1 and 2 represent our target tumor type of HR+ / HER2- and data from these patients will inform the design of the planned phase 3.

"After reviewing the totality of safety data, including patients receiving pelareorep plus the standard of care and those also receiving Tecentriq, the Safety Committee for AWARE-1 confirmed no significant toxicity resulting from treatment," said Dr. Rita Laeufle, Chief Medical Officer at Oncolytics Biotech. "The study is continuing as planned, recruiting additional patients and examining the combination of pelareorep, plus the standard of care plus Tecentriq.We look forward to presenting updated data at the ESMO Breast Cancer conference in May, which will describe meaningful changes to the tumor microenvironment, evidence of tumor infection, and of course, our biomarker correlated to immunogenic response and viral replication." Read this full press release and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

Other recent developments in the biotech industry include:Hoth Therapeutics, Inc. (NASDAQ: HOTH) recently announced it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects toprevent the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) atMassachusettsGeneral Hospital (MGH).

Hoth and Voltron, with the support of MGH, will work jointly on exploring and developing this SAV technology as a means to aid patients at risk of being infected with COVID-19. The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology which received Department of Defense (DoD) funding has demonstrated proof of concept in Lassa Fever, an emerging infectious disease. HaloVax intends to use these same SAV principles to assist in the development of a potential vaccine against the COVID-19 pandemic.

ADMA Biologics, Inc. (NASDAQ: ADMA) a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, recently announced financial results for the third quarter and nine months ended September 30, 2019, and provided an overview of its recent corporate achievements.

"To date, 2019 has been a transformational year for ADMA, marked most importantly by the recent re-launch and launch, respectively, and first commercial sales of our lead assets BIVIGAM and ASCENIV, both indicated for the treatment of patients with primary humoral immunodeficiency (PI)," said Adam Grossman, ADMA's President and Chief Executive Officer. "Our commercial rollouts are off to an encouraging early start for our IVIG brands.As we look ahead to the remainder of 2019 and into 2020, we remain focused on maximizing these initial product launches and executing on several strategic corporate initiatives aimed at growing our overall revenues, including potentially expanding the capacity at our manufacturing facility, opening new plasma collection centers, as well as growing our commercial team and hiring additional staff to support the anticipated production ramp up for 2020 and beyond."

Pfizer Inc. (NYSE: PFE) announced recently that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy. The study also included an active control arm, dupilumab, a biologic treatment administered by subcutaneous injection, compared with placebo.

"It was helpful to study abrocitinib in combination with topical therapies to provide data relevant to the real-world setting," said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. "The addition of an active control was also important to better understand the significance of this potential new medicine and we're encouraged by the positive data from this trial."

Aytu BioScience, Inc. (NASDAQ: AYTU) announced yesterday that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.

Aytu expects delivery of its first shipment of 100,000 tests this week. The Company has been in discussions with healthcare distributors, healthcare institutions, medical practices, and government agencies and is working quickly to begin distribution into the U.S. healthcare supply chain.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM expects to be compensated fifty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information: Media Contact email:[emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

See the rest here:
Biotech Brief: Why Oncolytic Viruses are Becoming a Potent Weapon Against Cancer - PRNewswire

What to read while youre self-isolating to avoid the coronavirus? How about books about all the various plagues humankind has survived before? There are classics like Giovanni Boccaccios 1353 classic The Decameron, about Italian aristocrats who flee the bubonic plague in Florence, or Daniel Defoes 1722 novel A Journal of the Plague Year, an account of the Black Death in London half a century before.

There are many more recent works about pandemics, some nonfiction, some historical fiction, some speculative fiction. On March 8, Stephen King resisted comparisons of the current crisis to his 1978 novel The Stand, set in a world where a pandemic has killed 99% of the population. King tweeted, No, coronavirus is NOT like THE STAND. Its not anywhere near as serious. Its eminently survivable. Keep calm and take all reasonable precautions.

Despite Kings protestations, readers often look to books to help explain real-world phenomena, especially in bewildering times like these. Here are a few more plague books to consider.

Fiction

Pale Horse, Pale Rider (1939) by Katherine Ann Porter is a short novel set during the influenza pandemic of 1918, which killed five times as many Americans as did World War I. Its main character, Miranda, is a young reporter who falls in love with a soldier; the books fever-dream style captures the experience of the disease.

The Andromeda Strain (1969) by Michael Crichton is a bestselling techno-thriller that begins when a military satellite crashes to earth and releases an extraterrestrial organism that kills almost everyone in a nearby small town. Then things get bad.

Love in the Time of Cholera (1985) by Gabriel Garca Mrquez is the great Colombian authors beguiling tale of a 50-year courtship, in which lovesickness is as debilitating and stubborn as disease.

The MaddAddam Trilogy by Margaret Atwood, which includes Oryx and Crake (2003), The Year of the Flood (2009) and MaddAddam (2013), is a masterwork of speculative fiction by the author of The Handmaids Tale. Set in a near future in which genetic engineering causes a plague that almost destroys humanity, its savagely satirical, thrilling and moving.

The Road (2006) by Cormac McCarthy is a bleak, beautifully written, Pulitzer Prize-winning novel set after an unspecified extinction event has wiped out most of humanity. An unnamed man and boy travel on foot toward a southern sea, fending off cannibals and despair.

Nemesis (2010) by Philip Roth is the authors 31st and last novel, a sorrowful story set in Newark, N.J., in 1944, as the United States is in the grip of the polio epidemic that killed and disabled thousands of children.

Station Eleven (2014) by Emily St. John Mandel is a bestselling novel about a group of actors and musicians traveling through the Great Lakes region in future years after a mysterious pandemic called the Georgian flu has killed almost everyone.

The Old Drift (2019) by Namwalli Serpell is a dazzling debut novel set in Zambia, spanning a century but focusing in part on the disaster wrought in that country by the HIV/AIDS epidemic.

Nonfiction

The Coming Plague: Newly Emerging Diseases in a World Out of Balance (1995) by Laurie Garrett is a Pulitzer Prize-winning reporters clear-eyed look at how rapidly the modern world has changed the nature of disease, how important preparedness is and how endangered we are without it.

Spillover: Animal Infections and the Next Human Pandemic (2013) by David Quammen is the great science writers fascinating look at zoonotic diseases, such as AIDS and Ebola (and now coronavirus), that jump from animal species to ours.

See the rest here:
Books about pandemics to read in the time of coronavirus - Greater Milwaukee Today

The growth in protein expression market is due to rise in prevalence of chronic disease such as diabetes, cancer, autoimmune disorders, and cardiovascular diseases. Furthermore, pharmaceutical companies are significantly investing in R&D expenditure thereby propelling the market growth.

The global protein expression market is expected to reach $4 billion by 2026, registering a CAGR of 10.2% from 2018 to 2026, in terms of value.

Protein expression is defined as a biotechnological procedure, which includes generation of precise proteins. These proteins are formed through manipulation of gene expression in organisms of interest.

The procedure leads to expression of large amounts of recombinant gene in organisms. Furthermore, this has led to many possibilities of expression and isolation of heterologous proteins for research, clinical, and industrial purposes.

This, in turn, has led to advancements in genetic engineering and recombinant technologies. Significant advancements in the field of biotechnology have enabled expression and isolation of recombinant proteins on large scale.

Some of products which are used to perform protein expression present in the market include reagents, expression vectors, competent cells, instruments, and others.

These products are used in designing therapeutics and conducting research related to medicines.

Report: http://www.alliedmarketresearch.com/request-sample/6463

The factors that boost the growth of the protein expression market include surge in geriatric population and increase in prevalence of chronic diseases such as cancer. Moreover, increase in spending on protein research also fuel the growth of the protein expression market.

However, high monetary inputs associated with the production of protein products restrict the growth of the market. In addition, significant shortage of trained healthcare professionals and lack of local expertise also restrains the market.

Conversely, emergence of microfluids, along with growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The global protein expression market is segmented based on product, application, and region. Based on product, the market is bifurcated into reagents, expression vectors, competent cells, instruments, and services.

By application, it is divided into therapeutic, industrial, and research. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Report: http://www.alliedmarketresearch.com/6463

The Major Key Players Are:

Key Findings of the Study:

Access Full Report atwww.alliedmarketresearch.com/proteinket-A06098

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the rest here:
Protein Expression Market estimated to grow according to forecasts - WhaTech Technology and Markets News

Johnson has championed deregulation and divergence from the EU on GM

In the three years after the UK's referendum on EU membership, it was often said Brexit had monopolised the political agenda leaving precious little "bandwidth" for anything else. But who would have imagined an issue of such magnitude was about to emerge that would consign Brexit to the "and in other news" section of TV bulletins?

That the biggest Brexit story last week was that EU negotiator Michel Barnier had tested positive for coronavirus and David Frost, his UK counterpart, is self-isolating after showing symptoms, tells its own story.

A few critical and challenging issues had dominated the long debates over the UK's membership of the EU, while undeniably important topics, including the country's differences with Brussels over genetic modification and biotechnology, were relatively little discussed. However, UK prime minister Boris Johnson is going some way to correcting that.

Boris backs British biotech

Since securing his premiership and withdrawal from the EU, Johnson has repeatedly made a point of championing deregulation and divergence from the EU on GM as a Brexit boon for the UK and a priority for his administration. Johnson also appointed George Eustice, a longstanding and vocal critic of the EU approach, as Secretary of State at the Department for the Environment, Food and Rural Affairs (Defra).

Based rigidly on the precautionary principle, EU regulations both on planting GM crops and commercialising foods made from GMO ingredients are consideredby many scientists overly restrictive and lengthy. Over the years, governments and policymakers from across the political divide have sympathised with that view but could do no more than push for reform in Brussels.

Johnson now has the opportunity to put the UK on a different footing. His intended direction of travel is clear, though GM is a highly contentious issue that could challenge even his libertarian instincts.

There has been strong support for deregulation on biotech in the scientific community for many years, so Johnson's remarks have been welcomed enthusiastically by crop scientists.

Professor Jonathan Jones of The Sainsbury Laboratory crop research institute, a practitioner and energetic proponent of GM technology for three decades, bemoans the "glacial" progress of GM regulation, but says the Johnson rhetoric is "exciting".

However, he cautions: "Of course, he's not delivered everything he's promised in the past but I think he's serious on this one. How rapidly we get there from here I don't know. It's complicated."

Consumer fears easily provoked

A prime challenge is the consumer concern and suspicion GM has always attracted. This has engendered a highly cautionary approach by retailers, as reflected in a comment from Andrew Opie, director of food and sustainability at UK food retail trade body The British Retail Consortium, for this article. "Retailers do not currently sell genetically-modified food under their own brands and would not do so unless there is a change in consumer demand," Opie says.

"Activist groups often behave irresponsibly in terms of inflaming public fears about something that is totally benign"

Others would say consumer fears which, while borne partly out of the understandable natural caution people have about technology related to food, are stoked by misinformation and sensationalised reporting, resulting in the retailers' and public policy being led by the least well informed on the topic. "Activist groups often behave irresponsibly in terms of inflaming public fears about something that is totally benign," Prof. Jones contends.

Food manufacturers have also been somewhat reticent about supporting GM publicly, even if they recognise the benefits of the technology.

Asked by just-food for its view on where the UK should go on biotech, the UK food manufacturing representative body The Food and Drink Federation, states: "FDF believes that modern biotechnology, including genetic modificationand new breeding techniques, offers considerable potential to improve the quality and quantity of [the] food supply and could contribute to sustainability by helping to produce more food using fewer resources and with less impact on the environment. FDF recognises that the impact of biotechnology must be objectively assessed, based on sound science and evidence, and be underpinned by an effective regulatory landscape."

The recognition of the potential benefits but a reluctance to go into battle on behalf of GM can clearly be seen in that statement. While Prof. Jones brands current policies on GM as the "tyranny of the more risk-averse", he says he "totally understands the brand reputation pressures both manufacturers and retailers are under". They see "a little bit of upside in terms of cost reduction but a vast amount of downside in terms of risking damage to my precious brand".

All this means biotech has been somewhat friendless, not receiving the widespread support from the private sector that technological innovation in other fields often can. Its backing by "Big Agri" has obviously been significant globally but the associations within that sector help foster some of the distrust, giving environmental campaigners a potent focus for their activities that has resonated with the public.

Farmer support

The National Farmers Union has generally been more publicly supportive of GM, however. Helen Ferrier, chief science and regulatory affairs adviser at the NFU, says it supports a "proportionate and enabling" regulatory framework on GM.

Vicki Hird of food and environment pressure group Sustain, however, suggests the picture is more mixed. "There's a lot of farmers I know who aren't members of the NFU [who] have a position on GM and biotech which is quite different from the NFU," Hird says, adding that protection of their European market will be a prime concern for many, underlining the influence ongoing negotiations could have on the UK's biotech ambitions.

"The UK currently remains aligned with the EU in its approach to genetically modified food. The UK's stance beyond January 2021 will depend very much on the outcome of trade negotiations," the BRC's Opie says.

Gene-editing move?

Where there could be more immediate progress is in the field of new gene-editing techniques. Dr Richard Harrison, director of Cambridge Crop Research, part of the National Institute of Agricultural Botany (NIAB), is leading research utilising modern gene-editing techniques, including CRISPR-Cas9, to modify the genetic make-up of the Fusarium venenatum fungus, the mycoprotein source for meat substitute brand Quorn, owned by Philippines group Monde Nissin.

"We're trying to understand how the fungus uses different carbon sources, and also how it regulates responses to nitrogen as well, because if we could understand that, then we'd be able to use a far greater range of crop-based carbon sources to produce mycoprotein," Harrison explains.

Being able to vary what mycoprotein is fed on could broaden the options for how and where mycoprotein can be sustainably produced as a meat alternative. The research is funded by the Biotechnology and Biological Sciences Research Council, with Quorn manufacturer Quorn Foods, a subsidiary of Monde Nissin,as a project partner and co-funder.

However, Harrison stresses the objective is not to produce a genetically engineered Fusarium venenatum that Marlow Foods might then commercialise, but that the gene-editing techniques are being used as "a research tool to validate our hypotheses".

Speaking to just-food last year, then Quorn Foods CEO Kevin Brennan said the company would "never go anywhere near genetic modification". This is not surprising and is common position among food companies. Owing to a 2018 European Court of Justice ruling, any food produced from ingredients derived from the gene-editing processes Harrison's team is employing would be subject to the EU's GM regulations and would have to be labelled as containing GMOs.

Brennan said the research "provides underpinning science for alternative carbohydrates but also to support feed optimisation". He continued: "If we can understand at a granular level what the organism reacts to we can optimise feedstock to encourage the ideal growth".

Ironically, some older and less accurate mutagenesis techniques, such as using gamma radiation and chemicals to alter genetic profile, fall outside the EU regulation. "All scientists are asking for is an objective evaluation rather than emotive one," Harrison adds.

In common with many scientists, Harrison believes EU regulations on genetic modification and gene editing to be overly restrictive and an impediment to scientific progress, not least as it discourages private-sector investment. So, would there be greater commercial opportunities for food companies, and consequently more investment in research, if the UK were to diverge from EU biotech regulations?

"Would a more proportionate regulatory framework bring in more investment? I think the answer is yes"

Harrison has no doubt there would, and Prof. Jones concurs. "Would a more proportionate regulatory framework bring in more investment? I think the answer is yes."

The NFU's Ferrier also believes regulatory reform will boost investment. "What we're interested in as an organisation is that you're able to move from the research into private-sector R&D and then commercialisation, because as long as seed companies don't see the EU and the UK as somewhere that they want to invest in, then you can do as much brilliant science as you like but the UK, farmers, society, environment, won't get any of the benefit because it will just stay in the research community."

Climate emergency

With regard to the regulation of genetic technologies in food production overall, Harrison urges a strictly evidence-led approach, not least given the challenges posed by climate change.

"There is enormous potential to grow crops with fewer pesticides by using naturally-occurring, disease-resistance genes. You could do that through traditional breeding but that takes a long time and costs a lot of money. Genetic technology makes it a lot faster and we should really have access in the 21st century to those technologies because we rapidly need to reduce our greenhouse gas emissions. Genetic technology could really be a powerful tool to accelerate our decarbonisation of the foodchain."

Prof. Jones adds: "We need every tool in the toolbox to address the perfect storm of rising temperatures, greenhouse gas emissions and rising population."

While recognising the benefits of separating gene-editing technology from GM, Prof. Jones is concerned arguing in favour of this may unintentionally lend weight to the view that there is still something to be feared in genetic engineering. "There are literally dozens of technologies like that that would be fantastic for the sustainability of agriculture, that you can only really accomplish by moving genes from one plant to another or by moving genes between bacteria and plants which is something that's happened naturally in evolution scores of times," he says, strongly urging the government to follow through on its supportive stance on GM.

Nevertheless, gene editing could be the more immediate movethat is easier to negotiate politically and practically. It is also almost impossible to imagine the UK moving out of the transition period with an ECJ ruling featuring in its legislation. Ferrier believes the UK could also work with other member states, many of which were concerned by the ECJ ruling, to move EU opinion on the issue. "This is the opportunity to work with other member states who are similarly concerned about it. That is an area that the UK research sector can have a strength in and it is a really exciting area for developing products that farmers could grow."

While the UK government is so far holding to its December deadline, the coronavirus pandemic seems highly likely to result in the extension of the transition period. When it does finally leave the EU, the UK is likely, at the very least, to have a different regulatory approach to gene editing, if not immediately on GM overall.

When exactly the transition period will now end, however, may depend more on how successful scientists have been at understanding the genome of Covid-19 than the genetic composition of any food crop.

See more here:
If and when it has time, the UK must ponder its post-Brexit biotech options - just-food.com

The global Genetic Engineering market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Genetic Engineering market, offers profound understandings about the Genetic Engineering market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Genetic Engineering focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4360374

Manufacturer Detail

By Market Players:Thermo Fisher Scientific Inc., GenScript, Amgen Inc., Genentech, Inc., Merck KGaA, Horizon Discovery Group plc, Sangamo Therapeutics, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc.

By Application

By TypeArtificial Selection, Cloning, Gene Splicing, Others

The Genetic Engineering market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Genetic Engineering market. This report on Genetic Engineering has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Genetic Engineering research study by HNY Research offers collection of information and analysis for each facet of the Genetic Engineering market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-intraductal-papilloma-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Genetic Engineering report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4360374

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read the rest here:
2020-2025 Global and Regional Genetic Engineering Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Zymergen, one of the worlds foremost science and material innovation companies, today announced the acquisition of enEvolv, the global leader in ultra-high throughput microbial screening and engineering, accelerating Zymergens ability to deliver revolutionary new products to market by 20% and further advancing the pace and scale of bio-manufacturing.

This partnership crystalizes our long-held belief that the combination of high throughput genome engineering, powerful technology and new approaches to material science will push the biological manufacturing revolution into the mainstream, says Colin South, CEO of enEvolv. Zymergen is the technology leader in this domain and their high standards for research, coupled with their commitment to creating novel materials from biological sources, is truly unmatched in the industry. They are the only full stack product company that has invested in material science and chemistry capabilities in addition to manufacturing-scale genetic engineering, and we are truly excited to be joining their team and taking our work to the next level, together.

The enEvolv platform centers around biosensors, making it possible to search billions of individual engineered cells in a single day, detecting target molecules with exquisite sensitivity and specificity. These biosensors allow throughput dramatically exceeding existing industry capabilities, which are typically limited to only a few thousand searchable cells. enEvolvs core technology is built on multiple foundational patents licensed exclusively from the Church Lab at Harvard University and has been deployed successfully in multiple commercial applications.

Merging enEvolvs powerful technology to search ultra-large genomic libraries with Zymergens proven capabilities in engineering, automation and machine learning greatly enhances our ability to discover, design and commercialize biologically-manufactured materials across a wide spectrum of industries - starting with electronics, consumer care and agriculture, says Zymergen CEO Joshua Hoffman. This acquisition speeds our delivery of high performance and sustainable products to customers and further cements our leadership position in the bio-manufacturing space.

As part of the acquisition, the entire enEvolv organization will join Zymergen, including founder and COO Jay Konieczka and CEO Colin South. Already a global organization with offices across North America and Asia, this acquisition adds a Boston-area location to the Zymergen footprint, improving collaboration with East Coast partners and greatly enhancing Zymergens ability to attract talent from the rich science, technology and academic communities around New England.

As a researcher and entrepreneur myself, I am all too familiar with the roadblocks many in the community face when trying to take powerful new discoveries to market in a cost effective and scalable way, says George Church, Professor of Genetics and Director of the Center for Computational Genetics at Harvard Medical School, and co-founder of enEvolv. The Zymergen team has cracked the code and built a strong business that merges the best of biological and chemical research practices with lab automation and powerful machine learning capabilities to create revolutionary new materials that are both economically robust and ecologically sound. The combined talent and capacity of enEvolv and Zymergen will further accelerate the transformation in product and material manufacturing.

About Zymergen

Zymergen is a science and material innovation company rethinking biology and reimagining the world. A World Economic Forum Tech Pioneer, Zymergen partners with nature to create never-before imagined materials and products across industries from agriculture to electronics, personal care to pharmaceuticals, and more. The company creates sustainable materials that are in use today, creating value for Fortune 1000 companies with over $1 billion worth of products using Zymergen microbial innovations sold to date. Zymergens first commercially available product - a high performance optical film for advanced electronic applications - is launching in mid-2020, with a number of additional products coming in late 2020 and early 2021. At Zymergen we are partnering with nature to make tomorrow. To learn more please visit http://www.Zymergen.com.

About enEvolv, Inc

enEvolv is a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. enEvolvs platform is built on diverse strain libraries and ultra-high throughput screening that utilizes molecular sensor systems. enEvolv partners with leading companies in the animal feed, agriculture, pharmaceuticals, specialty chemicals, and materials industries.

Go here to read the rest:
Zymergen Announces Acquisition of enEvolv, Accelerating Ability to Deliver High-Value Products to Market - Business Wire

Genetic engineering refers to the set of technologies that directly manipulate on an organisms genes, change the genetic make up of cells and add one or more new traits that are not found in that organism. At the heart of all life is what we call DNA. It is responsible for the abundance of life on this Earth and the reason why we are the way we are. The genetic make-up of any organism is defined by DNA. In nature, the genetic nature never remains fixed.

Genetic engineering has a huge array of applications, for instance, surgery, animal husbandry, medicine, and agriculture. With genetic engineering, many crops species have developed immunity to most lethal diseases. Genetic engineering has also helped to increase yields at the farm. Today, wide-ranging crop species like wheat are genetically modified to achieve high nutritive value, and faster and higher productivity. These days, more and more countries are embracing genetically engineered crops to fight scarcity of food, offer highly nutritious foods, and grow and cultivate crops that are immune to various diseases and pests. Genetic engineering, in many ways, has heralded an age of agricultural revolution, which many hope will help wipe out malnutrition and starvation.

What is genetic engineering? Well, its when a gene of a particular organism is harnessed and the copy inserted into the DNA of another organism to modify its characteristics. An organism is any living thing such as humans, plants, and animals. To understand how genetic engineering works, it would be prudent to know how DNA works. Any organism has a cell. In the cell, there is DNA, which acts as an instructional manual for the entire body.

DNA is responsible for every characteristic of an organism, for example, in humans; its responsible for eye color, hair color, height and so on. So, to harvest the height gene from an organism, biologists use restriction enzyme (which resemble a scissor) to cut it out. The harvested height gene is then inserted into a second targeted organism. The targeted organism then reproduces, and the result is multiplication of organisms with the modified height. The same process applies to genetically modified foods.

Genes rarely ever comprise of a single genetic material. The more complex an organism becomes, the more genetic material it has. Much of it has no use and only a small fraction of it is responsible for our specific characteristics. For example, humans and apes share some 99% of their DNA. It is the rest 1% which can be used to create such spectacular differences.

It is also the amount from which active genetic material is extracted and introduced to a new host cell, usually bacteria. This allows it to perform or inherit a certain function from the new genetic material. If it sounds too tough to understand genetic engineering, just imagine that artificial insulin for diabetics is produced through this method.

The applications of this field are growing each day. One example is the production of insulin for diabetes patients. The field of medicine is reaping the benefits of genetic engineering. They have used the process to create vaccines and human growth hormones, changing the lives of many in the process. Gene therapy has been developed, which could possibly provide a cure for those who suffer from genetic illnesses.

It has also found a place of importance in research. As scientists successfully understand genetic engineering, they use it to resolve issues in current research methods. Most of these are done with the help of genetically modified organisms.

Statistics according to scientists at the Germanys University of Gttingen indicate that Genetically Modified Foods (GMO) increase crop yield by more than 22%. This is why most areas experiencing food shortage have taken up the use of GMOs to help reverse the trend.

Genetic modification greatly increases flavor of crops. For, instance, modification makes corn sweeter and pepper spicier. In fact, genetic modification has the capability to make difficult flavor a lot palatable.

Resistance to disease was the main reason for genetic engineering research. Genetically modified foods exhibit great resistance to various diseases. Just like vaccine, genetic codes are implanted into foods to fortify their immune system.

Genetic modification has enabled researchers to incorporate variety of nutrients like proteins, vitamins, carbohydrates and minerals in crops to accord consumers greater nutritive value. This aspect has helped many in the developing world who cannot afford a balanced diet every single day. In addition, genetic modification has gone a long way towards solving worldwide malnutrition. For instance, rice thats strengthened with vitamin A, referred to as golden rice, now assist in mitigating deficiency of vitamin A across the globe.

Statistically, GMOs have a much longer lifespan than other traditional foods. This means they can be transported to far destinations that lack nutritious foods without fear of going bad.

The use of molecular biology in vaccine creation has bore fruits so far according to FAO (Food and Agriculture Organization of the United Nations). Biologists have been able to genetically engineer plants to generate vaccines, proteins, and other important pharmaceutical products via a technique referred to as pharming.

Production of genetically modified foods involves less time, land, machinery and chemicals. This means you wont worry about greenhouse gas emission, soil erosion or environmental pollution. In addition, with increased productivity witnessed with genetically modified foods, farmers will use less farmland to grow crops. Not to mention, they are already growing foods like corn, cotton, and potatoes without using insecticides because genetically modified foods generate their own insecticides.

Scientists indulge in crop modification to achieve enhanced resistance to diseases and superior crop health. Genetically modified foods also have the capability to resist harsh weather conditions. All these factors lead to one thing: reduced risk of crop failure.

A research study by Brown University concluded that genetic modification normally blends proteins that are not naturally present in the organism, which can result in allergy reactions to certain groups people. In fact, some studies found out that GMOs had caused significant allergic reactions to the population. A separate research by the National Center for Health Statistics reported that food allergies in individuals under 18 years leaped from 3.4% in the year 1997-2999 to 5.1% in 2009-2011.

Although reports have pronounced that genetically modified foods have no impact on the environment, there are some noted environmental impacts. It has been established that GMOs grown in environments that do not favor them often lead to environmental damage. This is evident in the GMO cross-breeding whereby weeds that are cross-bred with modified plants are reported to develop resistance to herbicides. This, eventually, calls for added modification efforts.

The fact that GMOs take the same amount of time to mature, and same effort to cultivate and grow, they dont add any economic gain compared to traditional growing methods.

According to a research study by Food and Agriculture Organization (FAO), GMOs can transfer genes to other members of similar species or different species through a process called gene escape. This gene interaction might take place at different levels including plant, cell, gene or ecosystem. Trouble could arise if, for instance, herbicide resistant genes find way into weeds.

Research finding according to Iowa State University stipulates that some GMOs contain antibiotic characteristics that boost your immunity. However, when consumed, their effectiveness dramatically reduces compared to the real antibiotics.

1. Identification of an organism that exhibits the desired trait or gene of interest.

2. Extracting the DNA from that organism.

3. Through a process called gene cloning, one desired gene (recipe) must be located and copied from thousands of genes that were extracted.

4. The gene is slightly modified to work in a more desirable way once it is inserted inside the recipient organism.

5. The transformation process occurs when new gene(s), called a transgene is delivered into cells of the recipient organism. The most common transformation technique uses a bacteria that naturally genetically engineer plants with its own DNA. The transgene is inserted into the bacteria, which then delivers it into cells of the organism being engineered.

6. The characteristics of the final product is improved through the process called traditional breeding.

Hawaii is well documented as a place where genetically modified papaya trees have been cultivated and grown since 1999. The harvested papayas are disseminated to markets such as the United States and Canada. The reason for modifying these papayas is the Papaya Ringspot virus that has caused havoc for many years. Also, Hawaii papayas have been modified to slow down their maturity to accord suppliers sufficient time to ship to the market.

Statistically, over 90% of soybeans available in the marketplace today are genetically engineered to naturally resist a herbicide known as Round Up. This enhanced resistance enables farmers to use a lot more Round Up to exterminate weeds.

Eggplant, also known as Zucchini, is another food product that is widely genetically modified. Genetically modified eggplant encompasses a protein, which gives it more resistance to insects.

Cotton is very susceptible to diseases, insects, and pests. It is heavily modified to boost yields and resistance to pests and diseases.

Corn also makes the list of the most genetically modified foods. Half of farmers in the United States grow corn that has been genetically modified. Most of the corn is utilized for human consumption and animal feed.

Sugar beets are surprisingly modified due to their high demand in countries like U.S., Canada, and Europe. Genetically modified sugar beets debuted in the United States markets in 2009. They are genetically modified to develop resistance to Round Up.

These days, dairy cows are increasingly being genetically modified with growth hormones to enable faster growth and beef up of yields.

Harnessed from rapeseed oil. According to studies, it is the most well know genetically modified oil in the world.

Most countries require that any genetically modified food be labeled. 64 countries across the world with an estimated world population of 64% already label GMOs, the entire European Union included. China also joined the bandwagon of labeling GMOs. Although genetically modified food companies are fighting against labeling, the battle may not be won in the near future.

Science has been able to genetically engineer animals and plants alike. While the animals are used in research or sold as a novelty pet item, the plants have a different purpose. Following the years of pesticide and insecticide use, most pests have developed an immunity to them. With the help of scientists that understand genetic engineering, farmers now benefit from seeds that have been engineered.

They are provided with traits from other plants that can naturally balance the plant-pest relationship. As expected, the use of such engineering has become heavily commercialized and is used to produce more attractive varieties of food.

Genetically modified food is not an experimental project. Foods that have been engineered to look, smell and taste better have found their place in the supermarket shelves since 1994. Thats twenty years ago and the trend has become habit. Apart from their looks, foods are produced simply for consumer convenience, such as seedless fruits.

As of now, soybean, cotton seed oil, corn and canola are the most advanced of the modified crops. Most of the livestock grown in the country is feed with crops that were genetically modified, making them partly genetically modified organisms in the long run. For those that understand genetic engineering, the growing use of the technology is quite alarming.

However, not all is wonderful in world of genetic engineering. It has been launched into controversy many times over the last decade. Since it is still a fledgling technology whose implications are yet not clear, there are many liberties taken with it. Lack of policy and laws makes it easy for research based companies to misuse the work of those that understand genetic engineering.

Most concerns regarding genetically modified food and animals are the ethical ramifications, while others are related to problems in the ecology and future misuse of the technology. As a result, the process and technology is highly regulated as of now.

Even with the regulations and laws being passed to reign in the rampant abuse of genetic engineering, the process is not in a hurry to stop. The government is pushing for one step at a time, such as labeling foods as GM Foods in markets to help the customers make their own choice. But the commercial advantages are quite high and further research will be able to possibly solve many of our health and poverty related issues. This is the biggest argument in the favor of engineering. Even so, it takes a lot many years to fully understand genetic engineering.

A true environmentalist by heart . Founded Conserve Energy Future with the sole motto of providing helpful information related to our rapidly depleting environment. Unless you strongly believe in Elon Musks idea of making Mars as another habitable planet, do remember that there really is no 'Planet B' in this whole universe.

Read the rest here:
What is Genetic Engineering and Pros and Cons of ...

Imagine computers taking over the world. This scenario has been the grounds for many movies such as The Terminator. The debate over whether AI is dangerous or not has been a popular topic since the birth of the technology. As Elon Musk cautioned at SXSW 2018, AI is far more dangerous than nukes.

The same can be said about CRISPR, the new genetic engineering tool with the potential to delay aging, cure cancer and forever change the human species for better or worse. While it has been slowly gaining traction in the media and was discovered as early as 1993, CRISPR remains widely unknown despite the magnitude of its potential.

In my work focusing on AI, carbon offsetting, blockchain and CRISPR, I'm seeking to understand the big problems that I believe we will tackle this century. I'm currently networking with promising biolabs in Japan to increase my CRISPR expertise, and I would like to share what I've learned.

Now is the time to start educating yourself about CRISPR, keeping an eye on the market and establishing yourself as an industry leader.

How have we already changed life itself?

We have been engineering life since the dawn of time through selective breeding, but after discovering DNA, scientists began to take the process to a whole new level.

In the 1960s and 70s, scientists used radiation to cause random mutations in the hopes of creating something useful by pure chance. Sometimes it worked. A famous 1994 example is the FLAVR SAVR tomato, which was given an extra gene to suppress the buildup of a rotting enzyme to increase its shelf life.

In 2016, the first baby was born using the three parent genetic technique for maternal infertility.

What is CRISPR?

CRISPR (clustered regularly interspaced short palindromic repeats) is part of bacteria's immune system against bacteriophages, viruses that inject their DNA and hijack bacterias genomes to act as factories.

When a bacterium survives this attack, it saves part of the genetic code of the virus to form a protein (e.g. Cas9), which in turn scans the bacterium's insides for virus DNA matching the sample. If it finds any, the virus DNA gets cut out, effectively repelling the attack. This DNA archive is what we call CRISPR.

Here's the game-changer: Scientists discovered that it is programmable. In other words, programming it will give us the ability to modify, add or remove DNA parts with relative ease. This has the potential to cut gene editing costs, reduce the time to conduct experiments and vastly lower the complexity of the process.

Its potential applications are not limited to genetic diseases, either. Being able to edit DNA is opening up research possibilities for fighting other diseases, including cancer. It has the potential to slow aging and extend our lifespan. It can alter our bodies, leading to talk that it could eventually give us superhuman powers.

Are ethical concerns warranted?

Just like GMOs, there is also a lot of controversy and ethical debate surrounding CRISPR. It is sometimes referred to as Pandora's box.

Every parent wants a healthy child, but once genetic modification becomes commonplace in reproduction, I predict it won't be long before purely aesthetic changes are requested. This could ultimately lead to a cliff between genetically enhanced and unenhanced humans, where designer babiesare considered superior.

We have come quite a long way since the initial discovery, but CRISPR is still in its infancy. As precise as Cas9 editing is, errors are being made. Should germinal genes be edited, these changes could potentially be passed on.

However, at this point, I do not believe the question is whether it is good or bad. We have already been altering human DNA and will continue to do so. In my opinion, improper regulations are only likely to incentivize less transparent research in a more dangerous environment.

What are some early stage best practices for industry leaders?

Progress is slow but steady. The topic is complex and is far less tangible than, say, blockchain. Investments will require very patient pockets, due to potential temporary bans on clinical research using CRISPR. But with the sheer magnitude of its potential, I believe there won't be any industry that won't be affected by it in the future.

If, like me, you're a business leader getting involved in this industry, there are a few best practices you can keep in mind. Should your regulator become too much of a roadblock for your project despite your best efforts to be transparent and compliant consider moving it to a different jurisdiction. I predict others will do the same if U.S. regulations become stricter and slow the process.

As with AI, it's important to apply necessary caution. Projects must be transparent and compliant with regulators. The danger, if regulators become too uncooperative, is that CRISPR projects will move to less regulated spaces. Avoid jurisdictions that turn a blind eye to riskier procedures and experiments.

I believe ethical concerns need to be addressed logically. We have already crossed many boundaries, and there will always be those who are willing to do what others are not. That's why it's in everyone's best interest to discuss ethical concerns and bring critical thinking as an active part of research and development.

Read the original post:
CRISPR: Its Potential And Concerns In The Genetic Engineering Field - Forbes